Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | PI4KA | P42356 | 2/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | GAPDH | P04406 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13238881 | 1.00 | EGFR (0.41) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL1140703 | 1.00 | EGFR (0.41) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL2950104 | 0.99 | EGFR (0.40) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL2950100 | 0.99 | EGFR (0.40) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL1980312 | 0.85 | ADORA3 (0.57) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL112551 | 0.85 | ADORA3 (0.57) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL7153500 | 0.85 | ADORA3 (0.57) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL13238880 | 0.85 | POLB (0.43) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL15759284 | 0.83 | LMNA (0.38) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL2955999 | 0.81 | BCHE (0.42) | ADORA3ADORA2BALDH1A1LMNABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | claimed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| US-9650360-B2 | Anti-mycobacterial drugs against tuberculosis | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2831056-B1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | THE UNIV OF GEORGIA RES FOUND INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20150050237-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| EP-2831056-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | The University Of Georgia Research Foundation, Inc (US) | 2015-02-04 | — | — | EP | disclosed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-7666639-B2 | Pharmaceutical compositions comprising plant deoxyribonucleoside kinase enzymes (dNK) capable of phosphorylating nucleoside analogs and to medical use of said dNKs derived from (Arabidopsis thaliana), loblolly pine (Pinus taeda), tomato (Lycopersicum esculentum), maize (Zea mays) or rice (Oryza sativa) | KNECHT WOLFGANG | 2010-02-23 | — | — | US | disclosed |
| EP-1974026-A2 | MUTANT DEOXYADENOSINE KINASE ENZYMES AND THEIR USE | ZGene A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| US-20070248543-A1 | Chicken Deoxycytidine and Deoxyadenosine Kinase Enzymes and Their Use | ZGENE A/S (DK) | 2007-10-25 | — | — | US | disclosed |
| US-20070202120-A1 | Yellow Fever Mosquito Deoxyribonucleoside Kinases And Its Use | ZGENE A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| WO-2007079753-A2 | MUTANT DEOXYADENOSINE KINASE ENZYMES AND THEIR USE | ZGENE A/S (DK) | 2007-07-19 | — | — | WO | disclosed |
| US-20060230467-A1 | Plant deoxyribonucleoside kinase enzymes and their use | KNECHT WOLFGANG | 2006-10-12 | — | — | US | disclosed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060230467-A1 | Plant deoxyribonucleoside kinase enzymes and their use | PNKP, DTYMK, NADK | EGFR 3635/4885ERBB2 2459/4885ADORA3 1168/4885 |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | TKT, DHFR, DTYMK | EGFR 3878/4885ERBB2 2901/4885ADORA3 407/4885 |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | EGFR 4439/4885ERBB2 3473/4885ADORA3 235/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | EGFR 670/4885ERBB2 927/4885ADORA3 130/4885 |
| US-20150050237-A1 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS | FNTB, ABCC1, TBCD | EGFR 3011/4885ERBB2 3885/4885ADORA3 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.